Encore Medical, Inc.

Date of Prospectus: March 24, 2026

Encore Medical, Inc. Eyes \$15 Million IPO to Disrupt Stroke and Migraine Markets with Next-Gen Heart Device

Encore Medical, Inc. (NYSE American: EMI) is launching its highly anticipated initial public offering, aiming to raise \$15 million to fuel clinical trials, U.S. market entry, and global expansion for its innovative septal closure technologies. With a differentiated product suite targeting the lucrative stroke and migraine markets, Encore is positioning itself for rapid growth and value creation in the structural heart device sector.

IPO Snapshot: Key Terms and Offer Details

Encore Medical is offering 3 million shares of common stock at an expected price of \$5.00 per share, with a 15% over-allotment option. The company will trade under the symbol EMI on the NYSE American exchange. The total offer size is \$15 million (plus the over-allotment), and there will be 6.7 million shares outstanding post-offering (before exercise of the over-allotment option).

• IPO Symbol: EMI
• Offer Price: \$5.00 per share
• Shares Offered: 3,000,000
• Offer Size: \$15 million (+15% over-allotment option)
• Shares Outstanding Post-IPO: 6.7 million (before over-allotment)
• Listing Venue: NYSE American

Use of proceeds is earmarked for clinical trials, commercial growth, debt reduction, working capital, and general corporate purposes. This allocation underscores a growth-driven story with prudent balance sheet management—notably, U.S. clinical trial funding and accelerated commercialization form the core of the capital plan. The offer is underwritten by Oak Ridge Financial Services Group, Inc. and Dawson James Securities, Inc. [[18]].

Deal Parties and Structure

The IPO is managed by Oak Ridge Financial Services Group, Inc. and Dawson James Securities, Inc., both serving as underwriters. A 15% over-allotment (greenshoe) option is in place to support aftermarket stability. The involvement of specialized underwriters in healthcare and technology, as disclosed, signals credible deal execution and potential aftermarket support [[18]].

Company Overview: Encore Medical’s Business Model and Growth Pathway

Encore Medical, Inc. is a medical device innovator focused on the design, development, and commercialization of minimally invasive products for closing septal wall defects, especially Patent Foramen Ovale (PFO), a congenital heart defect affecting 25% of the population. PFOs are implicated in both ischemic strokes and migraines—a dual, high-value clinical market [[4]].

Encore’s flagship product is its PFO Closure Device—an implantable solution with:

• High closure rates and a low-profile, minimal-metal design
• Superior safety and efficacy in head-to-head clinical trials
• Device sizes: 20mm, 25mm, 30mm, 35mm
• CE-Mark approval and over 35,000 devices implanted globally
• FDA-approved pivotal trial underway in the U.S.

The company’s revenue streams are currently dominated by sales in Europe and other OUS (outside U.S.) markets, with the U.S. as the primary commercial target post-FDA approval. Encore leverages a network of 11 international distributors and is already active in 21 countries, with Germany, the Czech Republic, and Italy as notable markets [[11]].

Industry and Market Opportunity

Encore operates in the rapidly expanding structural heart closure device market. Key addressable segments include:

• PFO/Stroke Market: 139,000 U.S. patients annually, >\$1.5 billion immediate opportunity (based on \$11,000 ASP), with market penetration under one-third to date [[9]]
• PFO/Migraine Market: 11 million PFO closures potentially indicated, >\$120 billion annual market opportunity (based on \$11,000 ASP) [[10]]

These figures position Encore for exponential growth, with significant headroom in underpenetrated, high-burden disease categories.

Competitive Advantages and Differentiation

Encore’s PFO closure device claims several distinct competitive advantages:

• Low profile and minimal metal mass—reducing risks such as atrial fibrillation
• Ease of deployment and partial or full retrievability
• Septal puncture friendly, preserving future treatment options
• Head-to-head clinical data shows superior safety and closure rates versus major competitors (Abbott Amplatzer, W.L. Gore Cardioform) [[8]]
• Published results and a favorable U.S. FDA trial design

With an installed base of 35,000+ implants and strong margins on OUS sales, Encore is already demonstrating commercial and clinical traction [[7]].

Financial Health and Performance

Encore has shown strong sales growth and improving margins while investing heavily in clinical trials and regulatory activities. The following table summarizes Encore’s recent financial performance:

Encore’s sales have grown from \$1.43 million in 2023 to \$2.59 million in 2025, with gross margins increasing to 40.1%. Operating losses have narrowed, reflecting operating leverage and disciplined spending. The post-IPO balance sheet will be robust, with over \$12.7 million in cash and positive shareholders’ equity [[17]].

Management Team and Governance

Encore Medical, Inc. is led by a highly experienced executive team:

• Joseph Marino, President & CEO – 30 years as CEO/Chairman/Director of public companies; experience at Cardia, Inc. and Electro-Sensors (NASDAQ)
• Scott Robinson, VP Finance – Company Treasurer/Controller since inception; Wells Fargo background
• Peter Buonomo, Senior VP & Director – 25+ years in public company sales/marketing and IPO/M&A experience
• Gregory Steiner, Senior Financial Consultant – Ex-Ernst & Young, Grant Thornton, university accounting professor
• Board members include industry veterans from Medtronic, Mayo Clinic, and capital markets backgrounds [[15-16]]

Trends, Timing, and Market Environment

Encore is capitalizing on favorable trends in the structural heart and neurological device markets. The global burden of ischemic stroke and migraine is increasing, and device-based interventions are gaining physician and patient acceptance. The timing of the IPO aligns with:

• Significant clinical milestones—U.S. pivotal stroke and migraine trials underway, with FDA approval targeted within 24 months
• Strong commercial adoption in Europe and international markets, providing operational funding and validation
• Under-penetration of both stroke and migraine PFO closure markets, suggesting outsized long-term growth potential [[7, 10, 12, 13]]

The use of proceeds for U.S. clinical and commercial scale-up, coupled with OUS traction, positions Encore for accelerated revenue growth and market share gains.

Prospectus Deep Dive: Risk Factors, IP, and Growth Strategy

Key risk factors (as disclosed) include:

• Regulatory and clinical trial risk (timing, results, FDA approval)
• Market acceptance and competitive response from established players (Abbott, W.L. Gore)
• Concentration in PFO closure technology—exposure to single product risk
• Dependence on successful execution of U.S. clinical and commercial strategies
• Changes in reimbursement, regulatory, or competitive landscape [[3]]

Encore’s growth strategy centers on:

• Rapid completion of U.S. stroke pivotal trial (500 patients, 24-month approval timeline, ~\$7M capital need)
• Being the first device approved for PFO-related migraine in the U.S. (trial: 100-150 patients, 12-month follow-up, \$4M cost)
• Expanding international sales and distributor coverage
• Leveraging a differentiated, IP-protected portfolio (core patent extends to 2040)

Encore’s intellectual property portfolio features a key patent on its PFO device valid until 2040, with no known IP conflicts [[14]].

Ownership and Lock-ups

Post-IPO, there will be 6.7 million shares outstanding (prior to exercise of the over-allotment), with shares offered solely to the public. No details on cornerstone/anchor investors, pre-IPO disposals, or lock-up periods are disclosed.

Valuation and Peer Comparison

No explicit valuation multiples or peer comparison metrics are disclosed in the offering document. However, Encore identifies Abbott (Amplatzer) and W.L. Gore (Cardioform) as key product competitors in the PFO closure space [[8]].

Listing Outlook: Investor Takeaways and Estimated Performance

Encore Medical’s IPO offers investors direct exposure to two globally relevant, high-growth therapeutic markets—stroke and migraine—via a differentiated device platform with clinical validation and commercial proof-of-concept. The company’s:

• Expanding sales base, improving margins, and strong cash position post-IPO
• Seasoned management and board with medical device IPO and M&A track record
• Clear use of proceeds for clinical de-risking and U.S. launch

All point to a compelling growth narrative. The presence of a stabilization/over-allotment option and recognized underwriters adds aftermarket support.

Market conditions appear favorable: demand for stroke and migraine solutions is robust, and Encore’s U.S. pivotal trials are at an advanced stage. While regulatory and execution risks remain, the under-penetrated market and Encore’s competitive advantages suggest significant upside. Based solely on prospectus data, this IPO appears attractive for growth-oriented investors, with first-day trading likely to be robust if clinical and commercial milestones are maintained.

How to Access the Prospectus

Investors can obtain the registration statement and related documents at: www.sec.gov